TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive NIH Spent $181.3 Million on PR Last Year; House Probe Prompts Analysis of Spending July 12, 2013